Clinical Trial Update: Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients? [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating whether a GLP-1 receptor agonist can improve glucose tolerance in patients treated with antipsychotic medications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impaired Glucose Tolerance

Drugs mentioned

• GLP-1 receptor agonist

Snippet

Sponsor: Psychiatric Centre Rigshospitalet | Conditions: Impaired Glucose Tolerance Associated With Drugs | Phase 2 | Status: UNKNOWN